Iambic Therapeutics
Iambic Therapeutics is seeking a scientific and technology leader to design, build, and adopt agentic AI workflows for small-molecule drug discovery. This foundational role involves co-leading the creation of the Iambic Lab of the Future, integrating AI-driven molecular design with automated experimental workflows. The position requires driving efficiency in internal research and external partnerships while mentoring a high-performing team.
Headquarters
San Diego, California, United States
Company Size
51-200 employees
Founded
2020
Iambic Therapeutics is a biotech company applying an AI-driven platform — including its Enchant and NeuralPLexer technologies — to tackle the most challenging design problems in drug discovery and address unmet patient needs. Its high-throughput experimental platform converts novel molecular designs into biological insights, enabling faster development of potential best-in-class and first-in-class medicines. Iambic maintains a proprietary clinical pipeline targeting cancers such as HER2-driven tumors and breast cancer, and pursues collaborations with pharmaceutical partners, including Bayer, to advance AI-driven drug discovery.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Iambic Therapeutics.
Scientific Fellow, AI-Enabled Molecular Design
sanofi us
Scientific Leader - AI and Agentic Systems in Drug Discovery
Vertex
Scientific Fellow, AI-Enabled Molecular Design - all genders
sanofi us
Scientific Fellow, AI-Enabled Molecular Design
sanofi us
Senior Research Fellow (Small-Molecule Drug Discovery)
Nanyang Technological University
Business Lead, AI-native Small Molecule Discovery
BioLife Plasma Services